Skip to main content

Table 2 Definition of response to treatment with Onabotulinumtoxin A (OBT-A) and treatment duration in chronic migraine

From: Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers

Answer options n (%)
Reduction in the number of headache days required to define response to OBT-A
 ≥ 30% 16 (25.4)
 ≥ 50% 37 (58.7)
 < 30% provided that at least one of the following improves: 10 (15.9)
  • patient satisfaction with treatment and QoL
  • intensity of headache pain
  • use of medications for symptom relief
  • duration of headache attacks
Number of treatment cycles administered before considering a patient as a non-responder and discontinuing OBT-A
 2 1 (1.6)
 3 35 (55.6)
 4 14 (22.2)
 > 4 13 (20.6)
Criteria adopted for discontinuing OBT-A in responders
 None, as treatment should be maintained in the long-term 37 (58.7)
 Benefits for ≥6 months 21 (33.3)
 After 5 treatment cycles 3 (4.8)
 Achievement of <15 days/month with headache 2 (3.2)
  1. QoL quality of life